New NephSAP issue - "Chronic Kidney Disease and Progression"

By ASN Staff

NephSAP Volume 16, Number 3, September 2017

Find the full issue here.

Chronic Kidney Disease and Progression

Over 20 million people in the U.S. have CKD stages 1-5, and costs for advanced CKD exceed $47 billion annually. The 2017 Chronic Kidney Disease issue of NephSAP guides readers through the latest advances in clinical research for this common and costly disease. This issue of NephSAP provides a background of the clinical research published during the years 2015 and 2016, and covers 5 major areas of CKD research: epidemiology, biomarkers relevant to incidence and progression, genetic variants, cardiovascular disease, and modification of environmental CKD risk factors. New prediction formulas for kidney failure, Mesoamerican nephropathy, and advances in diabetes treatment, which may positively impact diabetic nephropathy, are highlighted. Genetic variants for CKD, particularly APOL1 variants confer high risk for non-diabetic kidney diseases, and were previously reviewed in NephSAP. However, for the first time, information on potential mechanisms whereby APOL1 variants induce podocyte apoptosis are described. Cardiovascular disease remains the principal cause of death for adults with CKD. This NephSAP outlines advances regarding biomarkers for detection of cardiovascular disease. The epidemiology of atrial fibrillation and heart failure are also discussed. The reader will also be provided with insight into topics ranging from management of CKD complications and associated comorbid conditions such as diabetes and obesity. Lastly, readers can also test their knowledge with a series of 30 questions. So, to keep up-to-date in nephrology, do not miss the CKD issue of NephSAP 2017.

Learning Objectives

  1. Review new information on the distribution of chronic kidney disease in the U.S. population and discuss projections of chronic kidney disease in the future.
  2. Examine new biomarkers for identifying chronic kidney disease and its progression
  3. Analyze the association between APOL1 variants and chronic kidney disease risk and examine potential modifiers.
  4. Outline new developments relating to clinical risk factors and emerging biomarkers for identifying and treating cardiovascular disease in CKD.
  5. Discuss novel data pertaining to obesity, nutrition, and weight loss interventions in CKD.
Category:
Subcategory:
Author:
ASN Staff
Article Image:
Body:

NephSAP Volume 16, Number 3, September 2017

Find the full issue here.

Chronic Kidney Disease and Progression

Over 20 million people in the U.S. have CKD stages 1-5, and costs for advanced CKD exceed $47 billion annually. The 2017 Chronic Kidney Disease issue of NephSAP guides readers through the latest advances in clinical research for this common and costly disease. This issue of NephSAP provides a background of the clinical research published during the years 2015 and 2016, and covers 5 major areas of CKD research: epidemiology, biomarkers relevant to incidence and progression, genetic variants, cardiovascular disease, and modification of environmental CKD risk factors. New prediction formulas for kidney failure, Mesoamerican nephropathy, and advances in diabetes treatment, which may positively impact diabetic nephropathy, are highlighted. Genetic variants for CKD, particularly APOL1 variants confer high risk for non-diabetic kidney diseases, and were previously reviewed in NephSAP. However, for the first time, information on potential mechanisms whereby APOL1 variants induce podocyte apoptosis are described. Cardiovascular disease remains the principal cause of death for adults with CKD. This NephSAP outlines advances regarding biomarkers for detection of cardiovascular disease. The epidemiology of atrial fibrillation and heart failure are also discussed. The reader will also be provided with insight into topics ranging from management of CKD complications and associated comorbid conditions such as diabetes and obesity. Lastly, readers can also test their knowledge with a series of 30 questions. So, to keep up-to-date in nephrology, do not miss the CKD issue of NephSAP 2017.

Learning Objectives

  1. Review new information on the distribution of chronic kidney disease in the U.S. population and discuss projections of chronic kidney disease in the future.
  2. Examine new biomarkers for identifying chronic kidney disease and its progression
  3. Analyze the association between APOL1 variants and chronic kidney disease risk and examine potential modifiers.
  4. Outline new developments relating to clinical risk factors and emerging biomarkers for identifying and treating cardiovascular disease in CKD.
  5. Discuss novel data pertaining to obesity, nutrition, and weight loss interventions in CKD.
Area(s) of Interest:
Date:
Thursday, September 14, 2017